VU ANH NGUYEN, MD
Osteopathic Medicine at Mckee Rd, San Jose, CA

6546472, Apr 8, 2003

Dec 29, 2000

09/751165

Lee W. Atkinson - Houston TX
Vu T. Nguyen - San Jose CA
Mark W. Peters - Santa Clara CA

Hewlett-Packard Development Company, L.P. - Houston TX

G06F 1206

711156, 711162, 713320

A computer system supports a fast hibernation operation to save power, while minimizing the amount of time it takes to enter the hibernation mode, and to resume normal operations. The system periodically stores data from system memory to non-volatile memory, such as a hard disk drive, during normal operations when the system is idle. The system includes activity monitors that detect when the data in memory pages is changed. The system periodically sweeps the monitors, and performs save operations to the non-volatile memory. When the system enters hibernation mode, the system determines which memory pages have been changed since the last save operation, and then saves those pages to memory. As an alternative, the system immediately can enter hibernation by supplying power to the memory pages that have not been saved since the last save operation. To implement this, independent switches under the control of the CPU of memory controller selectively turn off power to unsaved memory pages. The system can also implement a fast resume procedure by restoring the memory pages that have the highest priority, and saving the other pages in the background, or as need by the system devices.

5424289, Jun 13, 1995

Jul 30, 1993

8/099884

Heechung Yang - Palo Alto CA
Vu A. Nguyen - San Jose CA
Liang C. Dong - Mountain View CA
Patrick S.-L. Wong - Palo Alto CA

Alza Corporation - Palo Alto CA

A61K 3800

514 12

The present invention is directed to a pharmaceutical formulation of a therapeutic polypeptide together with a permeation-enhancing mixture of sodium salicylate and an oil to provide enhanced absorption of the polypeptide through the wall of the gastrointestinal tract, and particularly of the colon, after oral administration, the amount of oil being from about 10 wt % to about 30 wt %, preferably from about 15 wt % to about 25 wt %, of the total formulation and the amount of sodium salicylate being from about 70 wt % to about 90 wt %, preferably from about 75 wt % to about 85 wt %, of the total formulation. The polypeptide may be non-lyophilized. The pharmaceutical formulation is characterized as a solid, which provides a convenient and improved format for handling and storage and for the preparation of oral dosage forms (such as pills, capsules and delivery vessels) containing a homogeneous mixture of ingredients.

2003023, Dec 18, 2003

Dec 19, 2002

10/324239

Liang Dong - Sunnyvale CA, US
Patrick Wong - Burlingame CA, US
Steve Espinal - Mountain View CA, US
Vu Nguyen - San Jose CA, US

A61K031/522, A61K031/198, A61K009/22, A61K031/155

424/468000, 514/263360, 514/567000, 514/635000

The present invention includes a formulation and controlled release dosage form that enable the controlled release of therapeutic agents showing reduced absorption in the lower gastrointestinal tract. The formulation of the present invention includes a therapeutic agent that exhibits greater absorption in the upper GI tract than in the lower GI tract and a permeation enhancer, which serves to increase absorption of the therapeutic agent in the lower GI tract. The formulation of the present invention further includes a carrier that allows the formulation to transition to a bioadhesive gel in-situ after the formulation is dispensed within the GI tract and has had some opportunity to reach the surface of the GI mucosal membrane. The bioadhesive gel formed by the formulation of the present invention works to present effective concentrations of both the therapeutic agent and the permeation enhancer at the surface of the GI mucosal membrane over a period. The controlled release dosage form of the present invention is designed to deliver the formulation of the present invention at a desired release rate or release rate profile over a desired period of time.

2003019, Oct 23, 2003

Dec 18, 2002

10/324154

Liang Dong - Sunnyvale CA, US
Patrick Wong - Burlingame CA, US
Vu Nguyen - San Jose CA, US
Si-Hong Yum - Belmont CA, US
Anthony Chao - Cupertino CA, US
Peter Daddona - Menlo Park CA, US

A61K038/28, A61K038/21, A61K038/43, A61K031/715, A61K038/13

424/085700, 424/094100, 514/012000, 514/003000, 514/054000, 514/011000

The present invention includes a formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules. The formulation of the present invention includes a permeation enhancer, a hydrophilic macromolecule, and a carrier that exhibits in-situ gelling properties, such as a nonionic surfactant. The formulation of the present invention is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation of the present invention presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. The dosage form of the present invention incorporates the formulation of the present invention and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time.